Intellipharmaceutics International Inc. (IPCI)

[AngeloFoca]

Focalin XR and Seroquel XR received approval on time - that is - within the timeframe of patent expiration that would allow generics to go to market.

Pristiq generics are on the market and have 6 generic manufacturers supplying them - which is not many and FDA may see some benefit to competition by approving further manufacturers.

However... the FDA's primary objective is to lower drug prices by providing competition, and all others have SEVERAL manufacturers already supplying generics, and I do not believe FDA is in a hurry regarding other mfg's approvals since it would be inconsequential to the drug's price... for instance Glucophage XR has, I believe, 18 generics on the market... so there will be no benefit in lowering prices by approving any more.

I mention Glucophage because it is HUGE... the $1.2 BILLION market reflects sales of all the generics... and IF/WHEN we get approval it can immediately hit the market with Mallinckrodt.

A 5% slice of $1.2 billion = $60 million of which I believe IPCI will get approximately 50% or $30 million all going to the bottom line.

Oh happy days will be here then... da da, da da, da da da da!!!